首页> 外文期刊>Medical progress >Cardiovascular effects of rosiglitazeme vs pisglitaione
【24h】

Cardiovascular effects of rosiglitazeme vs pisglitaione

机译:罗格列酮与吡格列酮的心血管作用

获取原文
获取原文并翻译 | 示例
       

摘要

The thiazolidinediones-rosiglitazone and pioglitazone-both have cardiac adverse effects. A systematic review and meta-analysis of published studies has been carried out to compare the two drugs.The analysis included 16 studies (810,000 patients treated with a thiazolidin-edione for type 2 diabetes) in North America, the UK, and Taiwan. The average age of participants was > 60 years. Compared with pioglitazone, rosiglitazone was associated with significant increases of 16% in myocardial infarction, 22% in congestive heart failure, and 14% in mortality.
机译:噻唑烷二酮-罗格列酮和吡格列酮均具有心脏不良反应。对已发表的研究进行了系统的综述和荟萃分析,以比较这两种药物。该分析包括北美,英国和台湾地区的16项研究(810,000例接受噻唑烷二酮治疗2型糖尿病的患者)。参与者的平均年龄> 60岁。与吡格列酮相比,罗格列酮与心肌梗死显着增加16%,充血性心力衰竭增加22%和死亡率增加14%有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号